Pharming Group reported strong financial performance for the third quarter of 2026, with total revenues reaching $117.6 million, a 21% year-over-year increase. The results were driven by a return to growth for RUCONEST and significant expansion for Joenja (leniolisib) in both U.S. and international markets. Operating profit grew 89% to $29.9 million, and the company tightened its full-year 2026 revenue guidance to a range of $380 million to $390 million.
Key Highlights
- Joenja revenue increased 58% to $23.8 million, driven by higher U.S. uptake and new launches in Germany and Japan.
- RUCONEST revenue grew 14% to $93.8 million, reflecting U.S. demand stabilization and early seasonal inventory increases.
- Operating profit rose to $29.9 million from $15.8 million in the prior-year period, supported by revenue growth and R&D government grants.
- Cash and cash equivalents reached $190.9 million, bolstered by $32.4 million in cash flow from operations during the quarter.